X4 Pharmaceuticals Inc (STU:48Q) Stock News, Headlines & Updates
X4 Pharmaceuticals Inc Stock News from GuruFocus
- 1
Jun 27, 2024
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
Marketwired • 6:00am
Jun 03, 2024
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
May 29, 2024
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
Marketwired • 4:00pm
May 13, 2024
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Marketwired • 7:00am
May 09, 2024
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
Marketwired • 6:00am
May 08, 2024
X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial Overview
GuruFocus Research • 1:14am
Q1 2024 X4 Pharmaceuticals Inc Earnings Call Transcript
GuruFocus Research • 11:12pm
May 07, 2024
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Marketwired • 6:00am
May 01, 2024
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Apr 30, 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
Marketwired • 7:00am
Apr 29, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news